| U.S.News & World Report Best Hospitals
For the third consecutive year, Yale-New Haven Hospital has been named by
U.S.News Media Group to its national Honor Roll as one of the top hospitals in the United States. YNHH is ranked seventeenth in the U.S. according to the annual "America's Best Hospitals" rankings
.
In the cancer services category, Yale-New Haven Hospital moved from 29 to 21 after a significant increase in the reputation score. Our position is a reflection of the dedicated physicians and staff from Yale Cancer Center, Yale-New Haven Hospital, and Yale Medical Group. I look forward to working to help make the cancer center a top 10 center in the coming years.
Research Program Reviews
The mid-grant cycle reviews for each of the research programs are planned for this fall. Each program leader will be contacted in the coming weeks to schedule their program review.
External Scientific Advisory Board
We are in the initial planning stages for our annual External Scientific Advisory Board visit. The November meeting will include presentations from several of the research programs. Selected programs will be notified of the schedule in September.
|
Smilow Update
Building Tours
Yale Cancer Center, Yale-New Haven Hospital, and Yale School of Medicine faculty and staff members are invited to participate in a tour of Smilow Cancer Hospital. The guided tours are available several times a week and show the exciting progress made on the building, which is scheduled to open on October 26th.
To schedule a tour of Smilow Cancer Hospital, please call Loren Bartley at 688-7544.
Participants must wear pants (no skirts or shorts), and sturdy, closed-toed shoes without heels. For safety reasons, anyone not dressed appropriately will be denied access to the site. YNHH provides construction helmets and safety goggles for use during the tour.
|
Shared Resource Highlight
Biostatistics Program
The biostatistics shared resource provides active consultation for all phases of clinical and laboratory research in terms of planning, design, protocol preparation, and analysis. The program helps to identify quantifiable and relevant endpoints, which, in turn, allow for estimation of sample sizes and efficient estimation of scientifically interpretable parameters before the experiment is begun. During the conduct of clinical studies ongoing safety monitoring is offered. At completion, the program provides data analysis and assistance in manuscript preparation.
Daniel Zelterman, PhD, Director
(203) 785-5574
Learn More >>
|
Newly Opened Clinical Trials
HIC 0905005127
Principal Investigator: Mario Sznol, MD
A Phase I, Multicenter, Opened-label, Dose-escalation, Multidose Study of MDX-1203 in Subjects with Advanced/Recurrent Clear Cell Renal Cell Carcinoma or Relapsed/Refractory B-Cell Non-Hodgkin's Lympohoma
Learn More >>
HIC 0904005074 A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (greater than or equal to 4 cm) - IIIA Non-Small Cell Lung Cancer (NSCLC)
Learn More >>
HIC 0901004620
A Randomized, Multicenter, Open-label, Phase III Study of Adjuvant Lapatinib, Trastuzumab, their Sequence and their Combination in Patients with HER2/ErbB2 Positive Primary Breast Cancer
Learn More >>
|
Recent Publications
Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.
Brandsma JL, Shlyankevich M, Su Y, Zelterman D, Rose JK, Buonocore L.
Vaccine. 2009 Jul 14.
Read More >>
Characterization of DNA damage-dependent cell cycle checkpoints in a menin-deficient model.
Kottemann MC, Bale AE.
DNA Repair (Amst). 2009 Jul 14.
Read More >>
Prognosis For Mammographically Occult, Early-Stage Breast Cancer Patients Treated with Breast-Conservation Therapy.
Yang TI, Yang Q, Haffty BG, Moran MS.
Int J Radiat Oncol Biol Phys. 2009 Jul 18.
Read More >>
Reply to "Preoperative Chemotherapy and Potential Impact on Re-Excision for Early Breast Cancer"
Christy CJ, Grube BJ, Lannin DR.
Ann Surg Oncol. 2009 Jul 14.
Read More >>
TREX1 acts in degrading damaged DNA from drug-treated tumor cells.
Wang CJ, Lam W, Bussom S, Chang HM, Cheng YC.
DNA Repair (Amst). 2009 Jul 17.
Read More >>
Pharmacogenetics in pancreatic cancer.
Strimpakos AS, Syrigos KN, Saif MW.
JOP. 2009 Jul 6;10(4):357-60.
Read More >>
|
| |
| Inside Yale Cancer Center
Yale Cancer Center Answers
Our weekly radio program on WNPR - CT Public Radio is downloaded from our website over 5,000 times per month and is ranked second for cancer podcasts on iTunes. Over the last two years, the program has enjoyed a 70% increase in radio listeners on Sunday evenings. Hosted by Dr. Edward Chu and Dr. Francine Foss, 180 original 30-minute programs have been produced and are archived online in audio and written format.
Learn More >> |
Events
July 25; 8:00 AM
The Connecticut Challenge
Greenfield Hill, Fairfield
Learn More >>
July 27; 10:00 AM Yale Cancer Center Conference
WWW 201
Defining the Mechanisms of EGFR-Dependent Lung Tumorigenesis
Senior Research Scientist
Memorial Sloan-Kettering Cancer Center
July 28; 7:30 PM
The Connecticut Sun
The Yale Cancer Center Melanoma Program has partnered with CT Sun to raise awareness of skin cancer during their annual Day of Community Service. Join us at the game on Tuesday, July 28th at 7:30 PM.
To purchase tickets at a special discounted rate enter offer code: YALECC
Tickets >>
|
Submissions
Please submit your recent publication and grant announcements to:
Renee Gaudette
Director, Public Affairs and Marketing
renee.gaudette@yale.edu
|
|
|
